semaglutide weight loss drugs Newer Weight-Loss Not Cost-effective at Current Prices Weight loss drugs: 2024 expectations

[DOI] [PMC free article] [PubMed] [Google Scholar] 81.Ghusn W, Hurtado MD

What has changed, he said, is that more employers are looking for programs that pair drug coverage with clinical oversight and lifestyle support

Helping patients opt in for companies persistency programs may help them remember to take injections, get refills, and contact providers if clinical concerns occur

With a median treatment duration of 20 months, patients experienced a mean relative weight loss of 5% at 12 months, corresponding to absolute reductions of 2.8 kg at 6 months, 4.2 kg at 12 months, and 6.2 kg by the end of follow-up

Do not self-diagnose

Obese patients tend to have a number of comorbidities, or associated health conditions